Founded in 2008, GenePlanet offers a comprehensive portfolio of clinical, research, and preventive genomic solutions alongside fully integrated end-to-end NGS services for healthcare and research partners. Since BlackPeak Capital's 2023 investment, the company expanded from activity in 24 countries to more than 50 markets across Europe, Asia, Latin and Central America, and Africa, and integrated four bolt-on acquisitions. Its central laboratory hub in Zagreb is part of a certified Pan-European laboratory platform that includes additional hubs in Sweden and Hungary to enable faster turnaround. GenePlanet has launched proprietary tests and plans to broaden its product portfolio into oncology and rare-disease panels while accelerating expansion into high-value Western European and U.S. markets. The company intends to pursue aggressive organic growth and further acquisitions, targeting a full liquidity event for early investors within three to five years.

Total raised

$12M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2018